PFE catalysts
Catalysts and events linked to PFE, newest first.
PFE stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Fed Chair Warsh Signals Sustained Higher Rates to Combat Inflation 2026-09-28 · Down | dividend yield competition against higher risk-free cash yields | Source notes big pharma dividend stocks face competition from higher Treasury yields. | Not recorded |
| C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data 2026-09-26 · Up | combination therapy efficacy expansion for ELREXFIO franchise | C4 testing combination of cemsidomide with Pfizer's elranatamab. | Not recorded |
| C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS 2026-09-26 · Watch | combination therapy utility for elranatamab oncology portfolio | Cemsidomide evaluated in Phase 1b combination with Pfizer's elranatamab (ELREXFIO). | Not recorded |
| UN member states gather in New York to press for pandemic preparedness declaration 2026-09-26 · Up | renewed global preparedness spending can support vaccine and antiviral procurement expectations | health advocates called on UN member states to adopt a political declaration | Not recorded |
| Pfizer and Nvidia deploy $80M joint investment into CytoReason AI platform 2026-09-25 · Up | R&D pipeline optimization and reduced clinical discovery timelines | Pfizer partner on $80M CytoReason initiative. | Not recorded |
| Pfizer and NVIDIA Back $80M CytoReason Venture for AI Vaccine Adjuvant Discovery 2026-09-25 · Up | drug discovery pipeline optimization | Pfizer entered an $80M joint venture with CytoReason. | Not recorded |
| Pfizer and NVIDIA Form $80M AI Venture as Vaccine Discovery Investments Top $140M 2026-09-25 · Up | drug discovery cycle compression and R&D capital efficiency | Source notes Pfizer's participation in $80M joint venture into CytoReason. | Not recorded |
| Pfizer and NVIDIA invest $80M in CytoReason JV as vaccine AI funding tops $140M 2026-09-25 · Watch | R&D efficiency gains and pipeline acceleration via computational biology tools | $80M joint venture investment into CytoReason | Not recorded |
Do these developments change your position?
Review PFE alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-28Fed Chair Warsh Signals Sustained Higher Rates to Combat InflationPFE
- 2026-09-28Fed Chair Warsh Signals Sustained Higher Rates to Combat InflationPFE
- 2026-09-28Fed Chair Warsh Signals Sustained Higher Rates to Combat InflationDGS10 PFE
- 2026-09-26UN member states gather in New York to press for pandemic preparedness declarationEMBI MRNA PFE
- 2026-09-26C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker DataCCCC PFE-1.01%
- 2026-09-26C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker DataCCCC PFE-1.01%
- 2026-09-26C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMSCCCC PFE-1.01%
- 2026-09-25Pfizer and NVIDIA Commit $80M Joint Venture to AI Vaccine Adjuvant DiscoveryDNA NVDA PFE+3.95%
- 2026-09-25Pfizer and Nvidia Back $80M AI Computational Immunology VentureNVDA PFE+3.95%
- 2026-09-25Pfizer and Nvidia deploy $80M joint investment into CytoReason AI platformNVDA PFE+3.95%
- 2026-09-25Pfizer and NVIDIA Form $80M AI Venture as Vaccine Discovery Investments Top $140MNVDA PFE+3.95%
- 2026-09-25Pfizer and Nvidia Back $80M AI Computational Immunology VentureNVDA PFE+3.95%
- 2026-09-25Pfizer and Nvidia deploy $80M joint investment into CytoReason AI platformNVDA PFE+3.95%
- 2026-09-25Pfizer and NVIDIA Commit $80M Joint Venture to AI Vaccine Adjuvant DiscoveryDNA NVDA PFE+3.95%
- 2026-09-25Pfizer and NVIDIA Form $80M CytoReason Venture as Vaccine AI R&D ExpandsDNA PFE
- 2026-09-25Pfizer and NVIDIA Form $80M AI Venture as Vaccine Discovery Investments Top $140MDNA NVDA PFE+3.95%
- 2026-09-25Pfizer and NVIDIA Form $80M AI Venture as Vaccine Discovery Investments Top $140MDNA NVDA PFE+3.95%
- 2026-09-25Pfizer and NVIDIA Form $80M Joint Venture in AI Biopharma Platform CytoReasonDNA NVDA PFE+3.95%
- 2026-09-25Pfizer and NVIDIA Form $80M Joint Venture in AI-Driven Vaccine DiscoveryDNA NVDA PFE+3.95%
- 2026-09-25Pfizer and Nvidia deploy $80M joint investment into CytoReason AI platformNVDA PFE+3.95%
- 2026-09-25Pfizer and NVIDIA Back $80M CytoReason Venture for AI Vaccine Adjuvant DiscoveryNVDA PFE+3.95%
- 2026-09-25Pfizer and NVIDIA invest $80M in CytoReason JV as vaccine AI funding tops $140MDNA NVDA PFE+3.95%
- 2026-09-25Pfizer and Nvidia Back $80M AI Computational Immunology VentureNVDA PFE+3.95%
- 2026-09-25Pfizer and Nvidia Form $80M CytoReason AI Drug Discovery JVDNA NVDA PFE+3.95%
- 2026-09-25Pfizer and NVIDIA Commit $80M Joint Venture to AI Vaccine Adjuvant DiscoveryDNA NVDA PFE+3.95%
- 2026-09-25Pfizer and NVIDIA Form $80M CytoReason Venture as Vaccine AI R&D ExpandsDNA NVDA PFE+3.95%
- 2026-09-09Pfizer lifts full-year revenue outlook following $15.0B Q2 revenue beatPFE
- 2026-09-09Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year GuidancePFE
- 2026-09-09Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year GuidancePFE
- 2026-09-09Pfizer lifts full-year revenue outlook following $15.0B Q2 revenue beatPFE
- 2026-09-09Pfizer lifts full-year revenue outlook following $15.0B Q2 revenue beatPFE
- 2026-09-09Pfizer Beats Q2 Estimates at $15B Revenue and Raises Full-Year GuidancePFE
- 2026-09-01UNICEF Executive Board begins its second regular session in New YorkPFE UNICEF
- 2026-07-20Pfizer Targets $100B Weight-Loss Market via Metsera AcquisitionLLY PFE
- 2026-07-20Pfizer Targets $100B Weight-Loss Market via Metsera AcquisitionLLY PFE
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.